Daily Stock Analysis, DRV, DURECT CORPORATION, priceseries

DURECT CORPORATION. Daily Stock Analysis
Stock Information
Open
44.57
Close
42.32
High
47.02
Low
42.28
Previous Close
42.57
Daily Price Gain
-0.25
YTD High
47.02
YTD High Date
Jan 24, 2022
YTD Low
31.85
YTD Low Date
Jan 3, 2022
YTD Price Change
9.44
YTD Gain
28.71%
52 Week High
102.60
52 Week High Date
Feb 1, 2021
52 Week Low
31.51
52 Week Low Date
Dec 31, 2021
52 Week Price Change
-54.28
52 Week Gain
-56.19%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Mar 3. 2017
574.73
Mar 15. 2017
606.96
8 Trading Days
5.61%
Link
LONG
Apr 26. 2017
564.93
May 18. 2017
608.43
16 Trading Days
7.70%
Link
LONG
Feb 1. 2018
617.85
Feb 15. 2018
684.04
10 Trading Days
10.71%
Link
LONG
Dec 14. 2018
449.39
Jan 4. 2019
546.25
13 Trading Days
21.55%
Link
LONG
Nov 4. 2019
261.67
Nov 14. 2019
276.91
8 Trading Days
5.83%
Link
LONG
Mar 11. 2020
333.99
Mar 13. 2020
385.73
2 Trading Days
15.49%
Link
LONG
Mar 18. 2020
524.56
Mar 19. 2020
560.07
1 Trading Days
6.77%
Link
Company Information
Stock Symbol
DRV
Exchange
NASDAQ
Company URL
http://www.durect.com
Company Phone
4087771417
CEO
Felix Theeuwes
Headquarters
California
Business Address
10260 BUBB RD, CUPERTINO, CA 95014
Sector
Equity
Industry Category
Drugs
Industry Group
Drug Manufacturers - Other
CIK
0001082038
About

Description

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and drug delivery programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers for use as raw materials for pharmaceutical and medical devices under the LACTEL brand. Its product pipeline consists of multiple investigational drug candidates in clinical development, such as DUR-928, an endogenous, orally bioavailable small molecule that is in Phase 1 development stage to play a regulatory role in lipid homeostasis, inflammation, and cell survival. The company's advanced oral, injectable, and transdermal delivery technologies are designed to enable new indications and enhanced attributes for small-molecule and biologic drugs, including POSIMIR, an investigational analgesic product intended to deliver bupivacaine to provide up to 3 days of pain relief after surgery; and REMOXY ER, an investigational extended release pain relief drug. DURECT Corporation markets and sells its ALZET and LACTEL product lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has collaboration agreements with Santen Pharmaceutical Co., Ltd.; Impax Laboratories, Inc.; Zogenix, Inc.; and Pain Therapeutics, Inc. DURECT Corporation was founded in 1998 and is headquartered in Cupertino, California.